BUZZ-Scholar Rock rises after plan to resubmit application for muscle disorder drug

Reuters

Mar 03

BUZZ-<a href="https://laohu8.com/S/SRRK">Scholar Rock</a> rises after plan to resubmit application for muscle disorder drug

** Shares of drug developer Scholar Rock SRRK.O rise 6.2% to $46.16 premarket

** SRRK, in its earnings release, says it plans to resubmit application to market its experimental drug, apitegromab, to treat muscle disorder known as spinal muscular atrophy $(SMA)$

** Company says the move follows meeting with U.S. FDA and Catalent's Indiana facility, after which the regulator determined that no further action was required

** Apitegromab was previously declined approval in U.S. after drug regulator found issues arising from routine inspection of Catalent's Indiana fill-finish facility, which is owned by Novo Nordisk NOVOb.CO

** SRRK is banking on apitegromab to drive its growth and profitability

** The drug is also being tested for muscle preservation in obesity

** As of last close, SRRK stock was down 1.3% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616323689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616323689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616323689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616323689","market":"nz","top_or_hot":-1,"title":"BUZZ-Scholar Rock rises after plan to resubmit application for muscle disorder drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/SRRK\">Scholar Rock</a> rises after plan to resubmit application for muscle disorder drug </title></head><body><p>** Shares of drug developer Scholar Rock <span>SRRK.O</span> rise 6.2% to $46.16 premarket</p><p>** SRRK, <span>in its earnings release</span>, says it plans to resubmit application to market its experimental drug, apitegromab, to treat muscle disorder known as spinal muscular atrophy <a href=\"https://laohu8.com/S/SMA\">$(SMA)$</a></p><p>** Company says the move follows meeting with U.S. FDA and <a href=\"https://laohu8.com/S/CTLT\">Catalent</a>'s Indiana facility, after which the regulator determined that no further action was required</p><p>** Apitegromab was previously <span>declined</span> approval in U.S. after drug regulator found issues arising from routine inspection of Catalent's Indiana fill-finish facility, which is owned by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>NOVOb.CO</span> </p><p>** SRRK is banking on apitegromab to drive its growth and profitability</p><p>** The drug is also being tested for muscle preservation in obesity</p><p>** As of last close, SRRK stock was down 1.3% YTD </p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Scholar Rock rises after plan to resubmit application for muscle disorder drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Scholar Rock rises after plan to resubmit application for muscle disorder drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-03 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/SRRK\">Scholar Rock</a> rises after plan to resubmit application for muscle disorder drug </title></head><body><p>** Shares of drug developer Scholar Rock <span>SRRK.O</span> rise 6.2% to $46.16 premarket</p><p>** SRRK, <span>in its earnings release</span>, says it plans to resubmit application to market its experimental drug, apitegromab, to treat muscle disorder known as spinal muscular atrophy <a href=\"https://laohu8.com/S/SMA\">$(SMA)$</a></p><p>** Company says the move follows meeting with U.S. FDA and <a href=\"https://laohu8.com/S/CTLT\">Catalent</a>'s Indiana facility, after which the regulator determined that no further action was required</p><p>** Apitegromab was previously <span>declined</span> approval in U.S. after drug regulator found issues arising from routine inspection of Catalent's Indiana fill-finish facility, which is owned by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>NOVOb.CO</span> </p><p>** SRRK is banking on apitegromab to drive its growth and profitability</p><p>** The drug is also being tested for muscle preservation in obesity</p><p>** As of last close, SRRK stock was down 1.3% YTD </p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRRK","symbol_name":"Scholar Rock Holding Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL6N3ZR0ZY:1","article_id":"2616323689","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616323689","pubTimestamp":1772544977,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Scholar Rock rises after plan to resubmit application for muscle disorder drug** Shares of drug developer Scholar Rock SRRK.O rise 6.2% to $46.16 premarket** SRRK, in its earnings release, says i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRRK":"Scholar Rock Holding Corp","BK4139":"生物科技"},"translate_title":"BUZZ-Scholar Rock计划重新提交肌肉疾病药物申请后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":0.9},"content_text":"BUZZ-Scholar Rock rises after plan to resubmit application for muscle disorder drug ** Shares of drug developer Scholar Rock SRRK.O rise 6.2% to $46.16 premarket** SRRK, in its earnings release, says it plans to resubmit application to market its experimental drug, apitegromab, to treat muscle disorder known as spinal muscular atrophy $(SMA)$** Company says the move follows meeting with U.S. FDA and Catalent's Indiana facility, after which the regulator determined that no further action was required** Apitegromab was previously declined approval in U.S. after drug regulator found issues arising from routine inspection of Catalent's Indiana fill-finish facility, which is owned by Novo Nordisk NOVOb.CO ** SRRK is banking on apitegromab to drive its growth and profitability** The drug is also being tested for muscle preservation in obesity** As of last close, SRRK stock was down 1.3% YTD  (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}